<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Epilepsy in children: Comorbidities, complications, and outcomes</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Epilepsy in children: Comorbidities, complications, and outcomes</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Epilepsy in children: Comorbidities, complications, and outcomes</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Angus Wilfong, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Douglas R Nordli, Jr, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John F Dashe, MD, PhD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 19, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H624823784"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The impact of epilepsy on the child is determined by many factors other than recurrent seizures. This topic provides an overview of the comorbidities, complications, and outcomes of epilepsy in children.</p><p>Other aspects of seizures and epilepsy in children are presented elsewhere:</p><p> <a class="medical medical_review" href="/z/d/html/6199.html" rel="external">Seizures and epilepsy in children: Classification, etiology, and clinical features</a><br/> <a class="medical medical_review" href="/z/d/html/6218.html" rel="external">Seizures and epilepsy in children: Clinical and laboratory diagnosis</a><br/> <a class="medical medical_review" href="/z/d/html/6203.html" rel="external">Seizures and epilepsy in children: Initial treatment and monitoring</a><br/> <a class="medical medical_review" href="/z/d/html/101361.html" rel="external">Seizures and epilepsy in children: Refractory seizures</a><br/> <a class="medical medical_review" href="/z/d/html/6162.html" rel="external">Epilepsy syndromes in children</a></p><p class="headingAnchor" id="H705455119"><span class="h1">PSYCHIATRIC AND BEHAVIORAL HEALTH</span><span class="headingEndMark"> — </span>Children with epilepsy are at increased risk for psychologic, behavioral, cognitive, neurologic, academic, and social problems caused by their chronic neurologic condition, which may have a significant impact on quality of life independent of the seizures [<a href="#rid1">1-8</a>]. Frequent subclinical or subtle seizures may also have a direct impact [<a href="#rid9">9</a>].</p><p class="headingAnchor" id="H2101292255"><span class="h2">Depression and suicidality</span><span class="headingEndMark"> — </span>There is a high burden of mood disorders in children with epilepsy [<a href="#rid10">10-12</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevalence</strong> – In population-based studies, depression and anxiety are more prevalent in children with epilepsy compared with the general population. A 2011 systematic review of evidence from population-based studies suggested that the prevalence of depression in children with epilepsy was 12 to 14 percent [<a href="#rid13">13</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk associated with antiseizure medications</strong> – Increased suicidality has been linked to several antiseizure medications in randomized placebo-controlled studies of patients with epilepsy over five years of age [<a href="#rid14">14</a>]. The elevated risk (0.43 versus 0.22 percent) was observed as early as one week after starting medication and continued though the 24 weeks of study observation. The effect was consistent in the 11 antiseizure medications studied, and the US Food and Drug Administration (FDA) considered this risk likely to be shared by all antiseizure medications. However, the actual suicidal risk is thought to be very low [<a href="#rid15">15</a>]. By contrast, the risk of stopping or avoiding treatment with antiseizure medications is much worse and can lead to serious harm and even death.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Screening</strong> – Patients taking antiseizure medications should be regularly monitored for emergence or worsening of suicidal ideation or depression [<a href="#rid11">11</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – An overview of the treatment of depression and the approach to the assessment of suicidality in children are discussed in separate topic reviews. (See  <a class="medical medical_review" href="/z/d/html/1230.html" rel="external">"Suicidal ideation and behavior in children and adolescents: Evaluation and management"</a> and  <a class="medical medical_review" href="/z/d/html/1231.html" rel="external">"Overview of prevention and treatment for pediatric depression"</a>.)</p><p></p><p class="headingAnchor" id="H3492817011"><span class="h2">Attention deficit hyperactivity disorder</span><span class="headingEndMark"> — </span>Recognition of attention deficit hyperactivity disorder (ADHD) in children with epilepsy is important because effective treatments exist, and ADHD has been associated with decreased health-related quality of life in children with epilepsy [<a href="#rid16">16</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevalence</strong> – In our experience, and that of others, ADHD is one of the most common psychiatric comorbidities in children with epilepsy, with a reported prevalence ranging from 12 percent in a general population-based survey to as high as 60 percent in patients with severe epilepsy treated at tertiary care epilepsy clinics [<a href="#rid16">16-18</a>]. Children with ADHD and epilepsy are more likely than those without epilepsy to manifest the predominantly inattentive subtype of ADHD, rather than the hyperactive-impulsive subtype [<a href="#rid16">16,19</a>]. (See  <a class="medical medical_review" href="/z/d/html/624.html" rel="external">"Attention deficit hyperactivity disorder in children and adolescents: Clinical features and diagnosis", section on 'Diagnostic criteria'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Screening</strong> – We recommend that all children with epilepsy undergo standardized psychoeducational testing through their school or in the clinic. The International League Against Epilepsy (ILAE) endorses annual screening for ADHD beginning at six years of age or at the time of epilepsy diagnosis, with re-evaluation after a change of antiseizure medication [<a href="#rid20">20</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – Once a diagnosis of ADHD is made, behavioral therapies are offered as first-line intervention. If academic problems persist, then therapy with stimulant medication is offered to all but the most unstable patients. Caregivers and classroom teachers are advised to monitor the child's seizure burden carefully when the stimulant medication is first introduced. In our experience, it is rare to see a significant deterioration in seizure control.</p><p></p><p class="bulletIndent1">Stimulants have not been well studied in patients with epilepsy because of concern that they may lower the seizure threshold, and patients with epilepsy were excluded from clinical trials establishing the safety and efficacy of stimulant medications. Although one dose-escalation study of sustained-release <a class="drug drug_pediatric" data-topicid="12600" href="/z/d/drug information/12600.html" rel="external">methylphenidate</a> in children with epilepsy found a slight increase in seizure frequency at high doses [<a href="#rid21">21</a>], other data, including several prospective studies, suggest that low to medium doses of methylphenidate are safe and effective, even in children with active seizures [<a href="#rid22">22-30</a>].</p><p></p><p class="bulletIndent1">The treatment of children and adolescents with ADHD is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/623.html" rel="external">"Attention deficit hyperactivity disorder in children and adolescents: Overview of treatment and prognosis"</a>.)</p><p></p><p class="headingAnchor" id="H1670598371"><span class="h1">COGNITIVE IMPAIRMENT</span><span class="headingEndMark"> — </span>Epilepsy is often accompanied by cognitive and developmental delay, including autism and language deficits [<a href="#rid31">31-36</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevalence and risk factors</strong> – One study compared 282 children with normal intelligence quotient (IQ) and a first recognized seizure with 147 healthy siblings and found that children with seizures scored lower on all neuropsychologic tests; 27 percent had a neuropsychologic deficit [<a href="#rid31">31</a>]. Risk factors for neuropsychologic impairment included a symptomatic/cryptogenic etiology, a second unprovoked seizure, use of antiseizure medications, and epileptiform activity on the initial electroencephalogram (EEG). Another study of population-based data found that academic underachievement, defined as performance one standard deviation below that predicted by assessed IQ, was present in 42 percent of children with active epilepsy [<a href="#rid37">37</a>]. Underachievement was attributed in part to reduced school attendance, specific cognitive deficits, younger age at onset of first seizure, and effects of antiseizure medications.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Screening</strong> – When developmental delay, intellectual impairment, and/or poor performance in school is overt, the child should be referred for appropriate evaluation. (See  <a class="medical medical_review" href="/z/d/html/6172.html" rel="external">"Intellectual disability (ID) in children: Clinical features, evaluation, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/6189.html" rel="external">"Intellectual disability in children: Evaluation for a cause"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – The approach to cognitive impairment and intellectual disability in children with epilepsy should be individualized and multidisciplinary. Optimal control of seizures is crucial. Depending upon the individual's needs, other interventions may include speech and language therapy, occupational therapy, physical therapy and rehabilitation, feeding therapy, vision and hearing services, family counseling and support, behavioral interventions, interventions to improve social participation, educational assistance, community integration, independent functioning and life skills learning, advocacy, and other aids. (See  <a class="medical medical_review" href="/z/d/html/6191.html" rel="external">"Intellectual disability (ID) in children: Management, outcomes, and prevention"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cognitive outcomes</strong> – Cognitive deficits are not limited to children with uncontrolled or symptomatic epilepsy. Neuropsychologic testing in children with new-onset focal and generalized epilepsy syndromes has demonstrated a range of cognitive abnormalities that tend to persist even with successful control of seizures [<a href="#rid38">38,39</a>]. In a prospective study of 69 children with new-onset focal or generalized epilepsy and normal imaging and neurologic examinations, abnormalities in arithmetic, psychomotor speed, attention, response inhibition, and fine motor dexterity were present at baseline and persisted, relatively unchanged, over a follow-up period of five to six years [<a href="#rid40">40</a>]. Children with generalized epilepsy tended to perform worse than those with focal epilepsy. More specific patterns of deficits have been described in association with some of the more common syndromes, including childhood absence and juvenile myoclonic epilepsy. (See  <a class="medical medical_review" href="/z/d/html/14450.html" rel="external">"Childhood absence epilepsy", section on 'Behavioral and psychiatric comorbidities'</a> and  <a class="medical medical_review" href="/z/d/html/17192.html" rel="external">"Juvenile myoclonic epilepsy", section on 'Cognition and behavior'</a>.)</p><p></p><p class="bulletIndent1">Children with intractable seizures may manifest a decline of cognitive function and memory with no attributable etiology other than the frequent seizures [<a href="#rid1">1</a>]. Data, particularly from animal research and human surgical specimens, increasingly indicate that the pervasive excitatory synaptic activity accompanying seizures, and probably interictal epileptiform discharges as well, lead to neuronal injury, abnormal neuronal sprouting, and interference with the normal pruning and complex rearrangement of neuronal connectivity that characterizes the developing nervous system [<a href="#rid41">41</a>]. Observational studies in children with epilepsy also suggest that poorly controlled seizures have a deleterious impact on cognition, particularly when they occur at a young age [<a href="#rid42">42-46</a>]. (See  <a class="medical medical_review" href="/z/d/html/101361.html" rel="external">"Seizures and epilepsy in children: Refractory seizures"</a>.)</p><p></p><p class="headingAnchor" id="H4112067165"><span class="h1">SLEEP DISTURBANCES</span><span class="headingEndMark"> — </span>Sleep disturbances are more common in children with epilepsy, compared with children without epilepsy, even among those without nocturnal seizures or sleep-related epilepsy syndromes [<a href="#rid47">47-49</a>]. Some authors describe a vicious cycle of interactions between epilepsy, antiseizure medications, and sleep, with multiple factors leading to sleep fragmentation, increased seizure frequency, and lowered seizure threshold [<a href="#rid50">50</a>]. Certain antiseizure medications can have a detrimental effect on sleep, including <a class="drug drug_pediatric" data-topicid="12698" href="/z/d/drug information/12698.html" rel="external">phenobarbital</a>, <a class="drug drug_pediatric" data-topicid="12702" href="/z/d/drug information/12702.html" rel="external">phenytoin</a>, <a class="drug drug_pediatric" data-topicid="13113" href="/z/d/drug information/13113.html" rel="external">carbamazepine</a>, and <a class="drug drug_pediatric" data-topicid="12873" href="/z/d/drug information/12873.html" rel="external">valproate</a> [<a href="#rid51">51,52</a>]. In turn, sleep disturbances can result in excessive daytime sleepiness, poor learning, behavioral disturbance, and reduced quality of life [<a href="#rid50">50</a>].</p><p>Sleep-related epilepsy syndromes are characterized by seizures that occur exclusively or predominantly during sleep or in the period shortly after arousal from sleep. Across the lifespan, these syndromes account for approximately 10 to 15 percent of all epilepsy syndromes. The clinical features, diagnosis, and treatment of common sleep-related epilepsy syndromes discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/97852.html" rel="external">"Sleep-related epilepsy syndromes"</a>.)</p><p>Patients with epilepsy may be sensitive to seizure precipitation by sleep deprivation, and children and their families should be instructed to adhere to good sleep hygiene and to obtain adequate amounts of sleep on a consistent basis. Children with suspected sleep disorders may benefit from an overnight sleep study (polysomnography) and referral to a sleep specialist. (See  <a class="medical medical_review" href="/z/d/html/6357.html" rel="external">"Assessment of sleep disorders in children"</a> and  <a class="medical medical_review" href="/z/d/html/97857.html" rel="external">"Overview of polysomnography in infants and children"</a>.)</p><p class="headingAnchor" id="H2052110401"><span class="h1">BONE HEALTH</span><span class="headingEndMark"> — </span>Screening for vitamin D deficiency and supplementation with calcium and vitamin D are low-risk interventions that are suggested for children and adults on long-term antiseizure medication therapy. (See  <a class="medical medical_review" href="/z/d/html/2063.html" rel="external">"Antiseizure medications and bone disease", section on 'Calcium and vitamin D'</a>.)</p><p>Both epilepsy and antiseizure medications are associated with adverse effects on bone health. Children with epilepsy who are treated with antiseizure medications are at increased risk for reduced bone density, impaired bone growth, and vitamin D deficiency [<a href="#rid53">53</a>]. Both enzyme-inducing and nonenzyme-inducing antiseizure medications as well as the ketogenic diet have been implicated in the risk of bone disease. However, few studies have rigorously evaluated strategies for prevention and treatment of bone disease in patients with epilepsy. (See  <a class="medical medical_review" href="/z/d/html/2063.html" rel="external">"Antiseizure medications and bone disease"</a> and  <a class="medical medical_review" href="/z/d/html/14438.html" rel="external">"Ketogenic dietary therapies for the treatment of epilepsy", section on 'Adverse effects'</a>.)</p><p class="headingAnchor" id="H1069926838"><span class="h1">ACTIVITY RESTRICTIONS</span><span class="headingEndMark"> — </span>Children with epilepsy may face questions about participating in athletics or other physical activities, and adolescents may encounter issues related to driving.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sports</strong> – In school-aged children with epilepsy, clinicians may be asked to provide medical clearance before a child can participate in certain sports or other physical activities. These decisions should be individualized, weighing not only the potential risks of participation but also the benefits of physical exercise and social engagement [<a href="#rid54">54</a>]. Factors to consider include the type of sport, the probability of a seizure occurring during the activity and related implications, the amount of supervision available during the activity, the patient's seizure type and severity, the consistency of any prodromal symptoms, relevant seizure precipitants, a history of seizure-related accidents or injuries, recent seizure control, degree of adherence to therapy, and the willingness of the patient and parents to take on risk. The International League Against Epilepsy (ILAE) has published a consensus-based guideline on this topic, which divides sports into three risk categories and proposes a decision-making framework for each risk category [<a href="#rid54">54</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Driving</strong> – States vary widely in driver licensing requirements for patients with epilepsy as well as the responsibilities of clinicians to notify state authorities [<a href="#rid55">55</a>]. This topic is discussed in more detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2226.html" rel="external">"Driving restrictions for patients with seizures and epilepsy"</a>.)</p><p></p><p class="headingAnchor" id="H2703733952"><span class="h1">QUALITY OF LIFE</span><span class="headingEndMark"> — </span>The psychologic stresses associated with epilepsy can be the major problem confronting the child or family. Health-related quality of life (HRQOL) can be affected even after a single seizure, but overall, deficits in HRQOL in children with epilepsy are related to seizure frequency and severity, as well as socioeconomic status [<a href="#rid56">56-59</a>]. The child may have difficulty at school because of peer ridicule, a poor academic performance as a result of limited cognitive function, low self-esteem, and/or depression.</p><p class="headingAnchor" id="H2689091874"><span class="h1">OUTCOMES</span></p><p class="headingAnchor" id="H1084946935"><span class="h2">Freedom from seizures</span><span class="headingEndMark"> — </span>The long-term prognosis for seizure cessation tends to be better in children than adults, particularly those who are neurologically intact [<a href="#rid60">60</a>]. In one community-based cohort, complete seizure remission occurred in one-half of children with nonsyndromic epilepsy [<a href="#rid61">61</a>]. Early seizure control, younger age of onset, and an absence of underlying brain disorder were associated with favorable outcomes.</p><p>In one study, 594 of 613 children with newly diagnosed epilepsy were followed for at least two years [<a href="#rid62">62</a>]. Seizure remission occurred in 74 percent; of these, 24 percent subsequently relapsed. Children with idiopathic generalized epilepsy and age of onset between five and nine years were more likely to have remission. Those with a remote symptomatic etiology, family history of epilepsy, frequent seizures, and slowing on the initial electroencephalography (EEG) were less likely to have remission. Approximately one-half of relapses occurred in children who had stopped or were tapering medication, while one-fourth occurred while on medication.</p><p>A smaller study followed 144 patients with epilepsy with onset before 16 years [<a href="#rid63">63</a>]. After 37 years follow-up, remission occurred in 67 percent, 86 percent of whom were off medication. Of the one-third of patients who did not achieve remission, 19 percent were drug-resistant (medically intractable), while 14 percent had experienced five-year remissions. A symptomatic origin was associated with failure to achieve remission and with medical intractability. Low intelligence quotient (IQ) was also a risk factor for intractability.</p><p class="headingAnchor" id="H2972085750"><span class="h2">Injuries</span><span class="headingEndMark"> — </span>Children with epilepsy are at increased risk for nonfatal injuries. In a population-based cohort study of over 11,000 children and young adults with epilepsy and over 45,000 controls, those with epilepsy were at increased risk for long bone fracture (hazard ratio [HR] 1.23, 95% CI 1.10-1.38), thermal injury (HR 1.49, 95% CI 1.27-1.75), and poisoning from medicinal products (HR 2.54, 95% CI 2.16-2.99) [<a href="#rid64">64</a>]. Other studies have reported similar results with respect to childhood fractures [<a href="#rid65">65-67</a>]. Proposed mechanisms for the increased risk of injuries include seizures themselves, adverse effects of anticonvulsants (eg, metabolic bone disease), inadvertent overdose, and increased access to medications in the home more generally. (See  <a class="medical medical_review" href="/z/d/html/2063.html" rel="external">"Antiseizure medications and bone disease"</a> and  <a class="medical medical_review" href="/z/d/html/2873.html" rel="external">"Prevention of poisoning in children", section on 'Prevention'</a>.)</p><p class="headingAnchor" id="H3756685848"><span class="h2">Mortality</span><span class="headingEndMark"> — </span>Children with epilepsy are at increased risk for premature death compared with children without epilepsy as well as adults with epilepsy [<a href="#rid68">68-71</a>]. The increased risk of death is highest in children with symptomatic epilepsy and is much lower in patients with idiopathic epilepsy [<a href="#rid72">72,73</a>]. Important causes of death directly attributable to epilepsy include convulsive status epilepticus, injuries, and sudden unexpected death in epilepsy (SUDEP). (See  <a class="medical medical_review" href="/z/d/html/2215.html" rel="external">"Sudden unexpected death in epilepsy"</a>.)</p><p>In a population-based study that included over 13,000 children with epilepsy from 2000 through 2011, the overall mortality rate was 8.8 deaths per 1000 person-years [<a href="#rid69">69</a>]. The annual risk for death was nearly fourfold higher among children with epilepsy compared with age-matched children without epilepsy (0.84 versus 0.22 percent). Comorbid developmental conditions (eg, congenital malformations, chromosomal abnormalities, intellectual disability, cerebral palsy), cardiovascular disorders, and injuries accounted for 18, 13, and 11 percent of deaths, respectively. Eight percent of deaths were attributed to seizure or status epilepticus and 7 percent to malignant neoplasms. The contribution of sudden unexpected death could not be estimated.</p><p>In another prospective cohort study with a mean follow-up of 40 years, 60 of 245 patients with epilepsy died, a rate threefold higher than expected in the general population [<a href="#rid68">68</a>]. The risk of death was especially high among children who were not in remission. Thirty percent of deaths were classified as SUDEP. Other causes of death included seizure and accidental drowning. (See  <a class="medical medical_review" href="/z/d/html/2215.html" rel="external">"Sudden unexpected death in epilepsy"</a>.)</p><p class="headingAnchor" id="H32399404"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/113981.html" rel="external">"Society guideline links: Seizures and epilepsy in children"</a>.)</p><p class="headingAnchor" id="H3734796249"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Children with epilepsy may have psychologic, behavioral, cognitive, neurologic, academic, and social problems caused by their seizures or by their chronic neurologic condition, independent of the seizures. (See <a class="local">'Psychiatric and behavioral health'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Depression and anxiety are more prevalent in children with epilepsy compared with the general population. Patients taking antiseizure medications should be regularly monitored for emergence or worsening of suicidal ideation or depression. (See <a class="local">'Depression and suicidality'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Recognition of attention deficit hyperactivity disorder (ADHD) in children with epilepsy is important because effective treatments exist, and ADHD has been associated with decreased health-related quality of life in children with epilepsy. (See <a class="local">'Attention deficit hyperactivity disorder'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Epilepsy is often accompanied by cognitive and developmental delay. When developmental delay, intellectual impairment, and/or poor school performance is overt, the child should be referred for appropriate evaluation. (See <a class="local">'Cognitive impairment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sleep disturbances are more common in children with epilepsy, compared with children without epilepsy, even among those without nocturnal seizures or sleep-related epilepsy syndromes. Some antiseizure medications can have a detrimental effect on sleep. (See <a class="local">'Sleep disturbances'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Both epilepsy and antiseizure medications are associated with adverse effects on bone health. Supplementation with calcium and vitamin D are low-risk interventions that are suggested for children and adults on long-term antiseizure medication therapy. (See <a class="local">'Bone health'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The long-term prognosis for seizure cessation tends to be better in children than adults, particularly those who are neurologically intact. Early seizure control, younger age of onset, and an absence of underlying brain disorder have been associated with favorable outcomes. (See <a class="local">'Freedom from seizures'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Children with epilepsy are at increased risk for nonfatal injuries. In addition, mortality is increased in children with epilepsy compared with those without. Important causes of death directly attributable to epilepsy include convulsive status epilepticus, injuries, and sudden unexpected death in epilepsy (SUDEP). (See <a class="local">'Injuries'</a> above and <a class="local">'Mortality'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Geerts A, Brouwer O, van Donselaar C, et al. Health perception and socioeconomic status following childhood-onset epilepsy: the Dutch study of epilepsy in childhood. Epilepsia 2011; 52:2192.</a></li><li><a class="nounderline abstract_t">Alfstad KÅ, Clench-Aas J, Van Roy B, et al. Psychiatric symptoms in Norwegian children with epilepsy aged 8-13 years: effects of age and gender? Epilepsia 2011; 52:1231.</a></li><li><a class="nounderline abstract_t">Taylor J, Jacoby A, Baker GA, Marson AG. Self-reported and parent-reported quality of life of children and adolescents with new-onset epilepsy. Epilepsia 2011; 52:1489.</a></li><li><a class="nounderline abstract_t">Russ SA, Larson K, Halfon N. A national profile of childhood epilepsy and seizure disorder. Pediatrics 2012; 129:256.</a></li><li><a class="nounderline abstract_t">Wagner JL, Wilson DA, Smith G, et al. Neurodevelopmental and mental health comorbidities in children and adolescents with epilepsy and migraine: a response to identified research gaps. Dev Med Child Neurol 2015; 57:45.</a></li><li><a class="nounderline abstract_t">Zhao Q, Rathouz PJ, Jones JE, et al. Longitudinal trajectories of behavior problems and social competence in children with new onset epilepsy. Dev Med Child Neurol 2015; 57:37.</a></li><li><a class="nounderline abstract_t">Lew AR, Lewis C, Lunn J, et al. Social cognition in children with epilepsy in mainstream education. Dev Med Child Neurol 2015; 57:53.</a></li><li><a class="nounderline abstract_t">Kaşak M, Çıtak Kurt AN, Tural Hesapçıoğlu S, Ceylan MF. Psychiatric comorbidity and familial factors in childhood epilepsy: Parental psychopathology, coping strategies, and family functioning. Epilepsy Behav 2023; 148:109444.</a></li><li><a class="nounderline abstract_t">Nicolai J, Ebus S, Biemans DP, et al. The cognitive effects of interictal epileptiform EEG discharges and short nonconvulsive epileptic seizures. Epilepsia 2012; 53:1051.</a></li><li><a class="nounderline abstract_t">Plevin D, Smith N. Assessment and Management of Depression and Anxiety in Children and Adolescents with Epilepsy. Behav Neurol 2019; 2019:2571368.</a></li><li><a class="nounderline abstract_t">Dagar A, Anand A, Pestana-Knight E, et al. Screening for suicidality and its relation to undiagnosed psychiatric comorbidities in children and youth with epilepsy. Epilepsy Behav 2020; 113:107443.</a></li><li><a class="nounderline abstract_t">Engel ML, Shanley R, Scal PB, Kunin-Batson A. Anxiety and depressive symptoms in adolescents and young adults with epilepsy: The role of illness beliefs and social factors. Epilepsy Behav 2021; 116:107737.</a></li><li><a class="nounderline abstract_t">Reilly C, Agnew R, Neville BG. Depression and anxiety in childhood epilepsy: a review. Seizure 2011; 20:589.</a></li><li class="breakAll">http://www.fda.gov/cder/drug/InfoSheets/HCP/antiepilepticsHCP.htm (Accessed on January 31, 2008).</li><li><a class="nounderline abstract_t">Mula M, Kanner AM, Schmitz B, Schachter S. Antiepileptic drugs and suicidality: an expert consensus statement from the Task Force on Therapeutic Strategies of the ILAE Commission on Neuropsychobiology. Epilepsia 2013; 54:199.</a></li><li><a class="nounderline abstract_t">Sherman EM, Slick DJ, Connolly MB, Eyrl KL. ADHD, neurological correlates and health-related quality of life in severe pediatric epilepsy. Epilepsia 2007; 48:1083.</a></li><li><a class="nounderline abstract_t">Davies S, Heyman I, Goodman R. A population survey of mental health problems in children with epilepsy. Dev Med Child Neurol 2003; 45:292.</a></li><li><a class="nounderline abstract_t">Thome-Souza S, Kuczynski E, Assumpção F Jr, et al. Which factors may play a pivotal role on determining the type of psychiatric disorder in children and adolescents with epilepsy? Epilepsy Behav 2004; 5:988.</a></li><li><a class="nounderline abstract_t">Hesdorffer DC, Ludvigsson P, Olafsson E, et al. ADHD as a risk factor for incident unprovoked seizures and epilepsy in children. Arch Gen Psychiatry 2004; 61:731.</a></li><li><a class="nounderline abstract_t">Auvin S, Wirrell E, Donald KA, et al. Systematic review of the screening, diagnosis, and management of ADHD in children with epilepsy. Consensus paper of the Task Force on Comorbidities of the ILAE Pediatric Commission. Epilepsia 2018; 59:1867.</a></li><li><a class="nounderline abstract_t">Gonzalez-Heydrich J, Whitney J, Waber D, et al. Adaptive phase I study of OROS methylphenidate treatment of attention deficit hyperactivity disorder with epilepsy. Epilepsy Behav 2010; 18:229.</a></li><li><a class="nounderline abstract_t">Koneski JA, Casella EB, Agertt F, Ferreira MG. Efficacy and safety of methylphenidate in treating ADHD symptoms in children and adolescents with uncontrolled seizures: a Brazilian sample study and literature review. Epilepsy Behav 2011; 21:228.</a></li><li><a class="nounderline abstract_t">Santos K, Palmini A, Radziuk AL, et al. The impact of methylphenidate on seizure frequency and severity in children with attention-deficit-hyperactivity disorder and difficult-to-treat epilepsies. Dev Med Child Neurol 2013; 55:654.</a></li><li><a class="nounderline abstract_t">Gucuyener K, Erdemoglu AK, Senol S, et al. Use of methylphenidate for attention-deficit hyperactivity disorder in patients with epilepsy or electroencephalographic abnormalities. J Child Neurol 2003; 18:109.</a></li><li><a class="nounderline abstract_t">Gross-Tsur V, Manor O, van der Meere J, et al. Epilepsy and attention deficit hyperactivity disorder: is methylphenidate safe and effective? J Pediatr 1997; 130:670.</a></li><li><a class="nounderline abstract_t">Wroblewski BA, Leary JM, Phelan AM, et al. Methylphenidate and seizure frequency in brain injured patients with seizure disorders. J Clin Psychiatry 1992; 53:86.</a></li><li><a class="nounderline abstract_t">Fosi T, Lax-Pericall MT, Scott RC, et al. Methylphenidate treatment of attention deficit hyperactivity disorder in young people with learning disability and difficult-to-treat epilepsy: evidence of clinical benefit. Epilepsia 2013; 54:2071.</a></li><li><a class="nounderline abstract_t">Salpekar JA, Mishra G. Key issues in addressing the comorbidity of attention deficit hyperactivity disorder and pediatric epilepsy. Epilepsy Behav 2014; 37:310.</a></li><li><a class="nounderline abstract_t">Radziuk AL, Kieling RR, Santos K, et al. Methylphenidate improves the quality of life of children and adolescents with ADHD and difficult-to-treat epilepsies. Epilepsy Behav 2015; 46:215.</a></li><li><a class="nounderline abstract_t">Rheims S, Herbillon V, Villeneuve N, et al. ADHD in childhood epilepsy: Clinical determinants of severity and of the response to methylphenidate. Epilepsia 2016; 57:1069.</a></li><li><a class="nounderline abstract_t">Fastenau PS, Johnson CS, Perkins SM, et al. Neuropsychological status at seizure onset in children: risk factors for early cognitive deficits. Neurology 2009; 73:526.</a></li><li><a class="nounderline abstract_t">Caplan R, Siddarth P, Vona P, et al. Language in pediatric epilepsy. Epilepsia 2009; 50:2397.</a></li><li><a class="nounderline abstract_t">Bhise VV, Burack GD, Mandelbaum DE. Baseline cognition, behavior, and motor skills in children with new-onset, idiopathic epilepsy. Dev Med Child Neurol 2010; 52:22.</a></li><li><a class="nounderline abstract_t">Kerr MP, Mensah S, Besag F, et al. International consensus clinical practice statements for the treatment of neuropsychiatric conditions associated with epilepsy. Epilepsia 2011; 52:2133.</a></li><li><a class="nounderline abstract_t">Rai D, Kerr MP, McManus S, et al. Epilepsy and psychiatric comorbidity: a nationally representative population-based study. Epilepsia 2012; 53:1095.</a></li><li><a class="nounderline abstract_t">Bailey K, Im-Bolter N. Language in childhood epilepsy: A systematic review and meta-analysis. Epilepsy Behav 2021; 114:107621.</a></li><li><a class="nounderline abstract_t">Reilly C, Atkinson P, Das KB, et al. Academic achievement in school-aged children with active epilepsy: a population-based study. Epilepsia 2014; 55:1910.</a></li><li><a class="nounderline abstract_t">Hermann BP, Jones JE, Jackson DC, Seidenberg M. Starting at the beginning: the neuropsychological status of children with new-onset epilepsies. Epileptic Disord 2012; 14:12.</a></li><li><a class="nounderline abstract_t">Oostrom KJ, Smeets-Schouten A, Kruitwagen CL, et al. Not only a matter of epilepsy: early problems of cognition and behavior in children with "epilepsy only"--a prospective, longitudinal, controlled study starting at diagnosis. Pediatrics 2003; 112:1338.</a></li><li><a class="nounderline abstract_t">Rathouz PJ, Zhao Q, Jones JE, et al. Cognitive development in children with new onset epilepsy. Dev Med Child Neurol 2014; 56:635.</a></li><li><a class="nounderline abstract_t">Marsh ED, Brooks-Kayal AR, Porter BE. Seizures and antiepileptic drugs: does exposure alter normal brain development? Epilepsia 2006; 47:1999.</a></li><li><a class="nounderline abstract_t">Berg AT, Zelko FA, Levy SR, Testa FM. Age at onset of epilepsy, pharmacoresistance, and cognitive outcomes: a prospective cohort study. Neurology 2012; 79:1384.</a></li><li><a class="nounderline abstract_t">Vasconcellos E, Wyllie E, Sullivan S, et al. Mental retardation in pediatric candidates for epilepsy surgery: the role of early seizure onset. Epilepsia 2001; 42:268.</a></li><li><a class="nounderline abstract_t">Cormack F, Cross JH, Isaacs E, et al. The development of intellectual abilities in pediatric temporal lobe epilepsy. Epilepsia 2007; 48:201.</a></li><li><a class="nounderline abstract_t">O'Callaghan FJ, Lux AL, Darke K, et al. The effect of lead time to treatment and of age of onset on developmental outcome at 4 years in infantile spasms: evidence from the United Kingdom Infantile Spasms Study. Epilepsia 2011; 52:1359.</a></li><li><a class="nounderline abstract_t">Hermann BP, Seidenberg M, Dow C, et al. Cognitive prognosis in chronic temporal lobe epilepsy. Ann Neurol 2006; 60:80.</a></li><li><a class="nounderline abstract_t">Gutter T, Brouwer OF, de Weerd AW. Subjective sleep disturbances in children with partial epilepsy and their effects on quality of life. Epilepsy Behav 2013; 28:481.</a></li><li><a class="nounderline abstract_t">Petropoulos MC, Bonaiuto K, Currier J, Pal DK. Practical aspects of childhood epilepsy. BMJ 2019; 367:l6096.</a></li><li><a class="nounderline abstract_t">Owens JA, Mindell JA. Pediatric insomnia. Pediatr Clin North Am 2011; 58:555.</a></li><li><a class="nounderline abstract_t">Gibbon FM, Maccormac E, Gringras P. Sleep and epilepsy: unfortunate bedfellows. Arch Dis Child 2019; 104:189.</a></li><li><a class="nounderline abstract_t">Legros B, Bazil CW. Effects of antiepileptic drugs on sleep architecture: a pilot study. Sleep Med 2003; 4:51.</a></li><li><a class="nounderline abstract_t">Bazil CW. Nocturnal seizures and the effects of anticonvulsants on sleep. Curr Neurol Neurosci Rep 2008; 8:149.</a></li><li><a class="nounderline abstract_t">Vestergaard P. Effects of antiepileptic drugs on bone health and growth potential in children with epilepsy. Paediatr Drugs 2015; 17:141.</a></li><li><a class="nounderline abstract_t">Capovilla G, Kaufman KR, Perucca E, et al. Epilepsy, seizures, physical exercise, and sports: A report from the ILAE Task Force on Sports and Epilepsy. Epilepsia 2016; 57:6.</a></li><li><a class="nounderline abstract_t">Krauss GL, Ampaw L, Krumholz A. Individual state driving restrictions for people with epilepsy in the US. Neurology 2001; 57:1780.</a></li><li><a class="nounderline abstract_t">Modi AC, King AS, Monahan SR, et al. Even a single seizure negatively impacts pediatric health-related quality of life. Epilepsia 2009; 50:2110.</a></li><li><a class="nounderline abstract_t">Benavente-Aguilar I, Morales-Blánquez C, Rubio EA, Rey JM. Quality of life of adolescents suffering from epilepsy living in the community. J Paediatr Child Health 2004; 40:110.</a></li><li><a class="nounderline abstract_t">Ronen GM, Streiner DL, Rosenbaum P, Canadian Pediatric Epilepsy Network. Health-related quality of life in children with epilepsy: development and validation of self-report and parent proxy measures. Epilepsia 2003; 44:598.</a></li><li><a class="nounderline abstract_t">Hamiwka L, Singh N, Niosi J, Wirrell E. Perceived health in children presenting with a "first seizure". Epilepsy Behav 2008; 13:485.</a></li><li><a class="nounderline abstract_t">Chin RF, Cumberland PM, Pujar SS, et al. Outcomes of childhood epilepsy at age 33 years: a population-based birth-cohort study. Epilepsia 2011; 52:1513.</a></li><li><a class="nounderline abstract_t">Berg AT, Testa FM, Levy SR. Complete remission in nonsyndromic childhood-onset epilepsy. Ann Neurol 2011; 70:566.</a></li><li><a class="nounderline abstract_t">Berg AT, Shinnar S, Levy SR, et al. Two-year remission and subsequent relapse in children with newly diagnosed epilepsy. Epilepsia 2001; 42:1553.</a></li><li><a class="nounderline abstract_t">Sillanpää M, Schmidt D. Natural history of treated childhood-onset epilepsy: prospective, long-term population-based study. Brain 2006; 129:617.</a></li><li><a class="nounderline abstract_t">Prasad V, Kendrick D, Sayal K, et al. Injury among children and young adults with epilepsy. Pediatrics 2014; 133:827.</a></li><li><a class="nounderline abstract_t">Hedström EM, Svensson O, Bergström U, Michno P. Epidemiology of fractures in children and adolescents. Acta Orthop 2010; 81:148.</a></li><li><a class="nounderline abstract_t">Cooper C, Dennison EM, Leufkens HG, et al. Epidemiology of childhood fractures in Britain: a study using the general practice research database. J Bone Miner Res 2004; 19:1976.</a></li><li><a class="nounderline abstract_t">Souverein PC, Webb DJ, Petri H, et al. Incidence of fractures among epilepsy patients: a population-based retrospective cohort study in the General Practice Research Database. Epilepsia 2005; 46:304.</a></li><li><a class="nounderline abstract_t">Sillanpää M, Shinnar S. Long-term mortality in childhood-onset epilepsy. N Engl J Med 2010; 363:2522.</a></li><li><a class="nounderline abstract_t">Selassie AW, Wilson DA, Malek AM, et al. Premature deaths among children with epilepsy - South Carolina, 2000-2011. MMWR Morb Mortal Wkly Rep 2014; 63:989.</a></li><li><a class="nounderline abstract_t">Thurman DJ, Logroscino G, Beghi E, et al. The burden of premature mortality of epilepsy in high-income countries: A systematic review from the Mortality Task Force of the International League Against Epilepsy. Epilepsia 2017; 58:17.</a></li><li><a class="nounderline abstract_t">Levira F, Thurman DJ, Sander JW, et al. Premature mortality of epilepsy in low- and middle-income countries: A systematic review from the Mortality Task Force of the International League Against Epilepsy. Epilepsia 2017; 58:6.</a></li><li><a class="nounderline abstract_t">Nesbitt V, Kirkpatrick M, Pearson G, et al. Risk and causes of death in children with a seizure disorder. Dev Med Child Neurol 2012; 54:612.</a></li><li><a class="nounderline abstract_t">Nickels KC, Grossardt BR, Wirrell EC. Epilepsy-related mortality is low in children: a 30-year population-based study in Olmsted County, MN. Epilepsia 2012; 53:2164.</a></li></ol></div><div id="topicVersionRevision">Topic 129781 Version 9.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22004073" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Health perception and socioeconomic status following childhood-onset epilepsy: the Dutch study of epilepsy in childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21446963" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Psychiatric symptoms in Norwegian children with epilepsy aged 8-13 years: effects of age and gender?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21569020" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Self-reported and parent-reported quality of life of children and adolescents with new-onset epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22271699" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : A national profile of childhood epilepsy and seizure disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25088717" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Neurodevelopmental and mental health comorbidities in children and adolescents with epilepsy and migraine: a response to identified research gaps.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25040537" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Longitudinal trajectories of behavior problems and social competence in children with new onset epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25330820" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Social cognition in children with epilepsy in mainstream education.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37748417" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Psychiatric comorbidity and familial factors in childhood epilepsy: Parental psychopathology, coping strategies, and family functioning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22554146" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The cognitive effects of interictal epileptiform EEG discharges and short nonconvulsive epileptic seizures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31191736" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Assessment and Management of Depression and Anxiety in Children and Adolescents with Epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33152581" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Screening for suicidality and its relation to undiagnosed psychiatric comorbidities in children and youth with epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33493808" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Anxiety and depressive symptoms in adolescents and young adults with epilepsy: The role of illness beliefs and social factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21741277" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Depression and anxiety in childhood epilepsy: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21741277" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Depression and anxiety in childhood epilepsy: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22994856" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Antiepileptic drugs and suicidality: an expert consensus statement from the Task Force on Therapeutic Strategies of the ILAE Commission on Neuropsychobiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17381442" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : ADHD, neurological correlates and health-related quality of life in severe pediatric epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12729141" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : A population survey of mental health problems in children with epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15582849" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Which factors may play a pivotal role on determining the type of psychiatric disorder in children and adolescents with epilepsy?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15237085" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : ADHD as a risk factor for incident unprovoked seizures and epilepsy in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30178479" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Systematic review of the screening, diagnosis, and management of ADHD in children with epilepsy. Consensus paper of the Task Force on Comorbidities of the ILAE Pediatric Commission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20493783" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Adaptive phase I study of OROS methylphenidate treatment of attention deficit hyperactivity disorder with epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21524941" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Efficacy and safety of methylphenidate in treating ADHD symptoms in children and adolescents with uncontrolled seizures: a Brazilian sample study and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23480530" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The impact of methylphenidate on seizure frequency and severity in children with attention-deficit-hyperactivity disorder and difficult-to-treat epilepsies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12693777" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Use of methylphenidate for attention-deficit hyperactivity disorder in patients with epilepsy or electroencephalographic abnormalities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9432523" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Epilepsy and attention deficit hyperactivity disorder: is methylphenidate safe and effective?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1548250" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Methylphenidate and seizure frequency in brain injured patients with seizure disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24304474" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Methylphenidate treatment of attention deficit hyperactivity disorder in young people with learning disability and difficult-to-treat epilepsy: evidence of clinical benefit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24835083" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Key issues in addressing the comorbidity of attention deficit hyperactivity disorder and pediatric epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25940104" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Methylphenidate improves the quality of life of children and adolescents with ADHD and difficult-to-treat epilepsies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27237724" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : ADHD in childhood epilepsy: Clinical determinants of severity and of the response to methylphenidate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19675309" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Neuropsychological status at seizure onset in children: risk factors for early cognitive deficits.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19624713" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Language in pediatric epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19702836" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Baseline cognition, behavior, and motor skills in children with new-onset, idiopathic epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21955156" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : International consensus clinical practice statements for the treatment of neuropsychiatric conditions associated with epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22578079" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Epilepsy and psychiatric comorbidity: a nationally representative population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33257294" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Language in childhood epilepsy: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25330985" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Academic achievement in school-aged children with active epilepsy: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22421240" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Starting at the beginning: the neuropsychological status of children with new-onset epilepsies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14654607" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Not only a matter of epilepsy: early problems of cognition and behavior in children with "epilepsy only"--a prospective, longitudinal, controlled study starting at diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24650092" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Cognitive development in children with new onset epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17201696" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Seizures and antiepileptic drugs: does exposure alter normal brain development?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22972641" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Age at onset of epilepsy, pharmacoresistance, and cognitive outcomes: a prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11240601" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Mental retardation in pediatric candidates for epilepsy surgery: the role of early seizure onset.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17241230" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The development of intellectual abilities in pediatric temporal lobe epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21668442" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : The effect of lead time to treatment and of age of onset on developmental outcome at 4 years in infantile spasms: evidence from the United Kingdom Infantile Spasms Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16802302" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Cognitive prognosis in chronic temporal lobe epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23892578" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Subjective sleep disturbances in children with partial epilepsy and their effects on quality of life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31712327" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Practical aspects of childhood epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21600342" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Pediatric insomnia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30266875" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Sleep and epilepsy: unfortunate bedfellows.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14592360" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Effects of antiepileptic drugs on sleep architecture: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18460284" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Nocturnal seizures and the effects of anticonvulsants on sleep.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25567416" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Effects of antiepileptic drugs on bone health and growth potential in children with epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26662920" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Epilepsy, seizures, physical exercise, and sports: A report from the ILAE Task Force on Sports and Epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11723263" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Individual state driving restrictions for people with epilepsy in the US.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19490034" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Even a single seizure negatively impacts pediatric health-related quality of life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15009574" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Quality of life of adolescents suffering from epilepsy living in the community.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12681011" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Health-related quality of life in children with epilepsy: development and validation of self-report and parent proxy measures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18617444" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Perceived health in children presenting with a "first seizure".</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21762447" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Outcomes of childhood epilepsy at age 33 years: a population-based birth-cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21710620" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Complete remission in nonsyndromic childhood-onset epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11879366" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Two-year remission and subsequent relapse in children with newly diagnosed epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16401617" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Natural history of treated childhood-onset epilepsy: prospective, long-term population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24733872" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Injury among children and young adults with epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20175744" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Epidemiology of fractures in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15537440" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Epidemiology of childhood fractures in Britain: a study using the general practice research database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15679512" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Incidence of fractures among epilepsy patients: a population-based retrospective cohort study in the General Practice Research Database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21175314" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Long-term mortality in childhood-onset epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25375069" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Premature deaths among children with epilepsy - South Carolina, 2000-2011.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27888514" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : The burden of premature mortality of epilepsy in high-income countries: A systematic review from the Mortality Task Force of the International League Against Epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27988968" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Premature mortality of epilepsy in low- and middle-income countries: A systematic review from the Mortality Task Force of the International League Against Epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22500675" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Risk and causes of death in children with a seizure disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22989286" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Epilepsy-related mortality is low in children: a 30-year population-based study in Olmsted County, MN.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
